Details of the Drug

General Information of Drug (ID: DM8J3VY)

Drug Name
Beremagene geperpavec
Indication
Disease Entry ICD 11 Status REF
Epidermolysis bullosa EC3Z Phase 3 [1]
Drug Type
Gene therapy
Cross-matching ID
UNII
AQN7K24KQU
DrugBank ID
DB17831
TTD ID
D8CW9E

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Collagen VII (COL7A1) TTBCOKN CO7A1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04491604) A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). U.S.National Institutes of Health.
2 Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022 Dec 15;387(24):2211-2219.